Core Viewpoint - Taimei Medical Technology (02576) has submitted a filing to the China Securities Regulatory Commission (CSRC) for the implementation of full circulation of its H-shares, indicating a strategic move to enhance liquidity and market presence [1] Group 1: Company Actions - The company has applied to convert a total of 363 million domestic shares into H-shares for listing on the Hong Kong Stock Exchange (HKEX) [1] - The conversion and listing will occur once all necessary approvals and compliance with applicable laws and regulations are obtained from relevant regulatory bodies, including the CSRC and HKEX [1] - According to the company's articles of association, there is no requirement to hold a shareholders' meeting to approve the conversion and listing [1]
太美医疗科技(02576)拟实施H股全流通